Publications for Karin Sennfält
Co-author map based on ISI articles 2007-

Keywords

year treatment technological sek prostate programme population patients pain msek hpv health estimate economic diffusion died cytology cost-effectiveness consequences cancer

Journal Articles

P. Bistoletti, Karin Sennfält and J. Dillner
  Cost-effectiveness of primary cytology and HPV DNA cervical screening
  International Journal of Cancer, 2008, 122(2), 372-376.
 Web of Science® Times Cited: 8

Lars Bernfort, Karin Sennfält and Olle Reichard
  Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
  Scandinavian Journal of Infectious Diseases, 2006, 38, 497-505.
 Web of Science® Times Cited: 11

Karin Sennfält, Per Carlsson and Eberhard Varenhorst
  Diffusion and Economic Consequences of Health Technologies in Prostate Cancer Care in Sweden, 1991-2002
  European Urology, 2006, 49(6), 1028-1034.
 Web of Science® Times Cited: 8

Karin Sennfält, G. Sandblom, Per Carlsson and Eberhard Varenhorst
  Costs and effects of prostate cancer screening in Sweden: a 15-year follow-up of a randomized trial
  Scandinavian Journal of Urology and Nephrology, 2004, 38(4), 291-298.
 Web of Science® Times Cited: 15

G Sandblom, Per Carlsson, Karin Sennfält and Eberhard Varenhorst
  A population-based study of pain and quality of life during the year before death in men with prostate cancer
  British Journal of Cancer, 2004, 90(6), 1163-1168.
 Web of Science® Times Cited: 25

Karin Sennfält, Per Carlsson, Gabriel Sandblom and Eberhard Varenhorst
  The estimated economic value of the welfare loss due to prostate cancer pain in a defined population
  Acta Oncologica, 2004, 43(3), 290-296.
 Web of Science® Times Cited: 5

Karin Sennfält, Per Carlsson, Johan Thorfinn, Jessica Frisk, Martin Henriksson and Eberhard Varenhorst
  Technological changes in the management of prostate cancer result in increased healthcare costs: a retrospective study in a defined Swedish population
  Scandinavian Journal of Urology and Nephrology, 2003, 37(3), 226-231.
 Web of Science® Times Cited: 8

Karin Sennfält, Martin Magnusson and Per Carlsson
  Comparison of hemodialysis and peritoneal dialysis - A cost-utility analysis
  Peritoneal Dialysis International, 2002, 22(1), 39-47.
 Web of Science® Times Cited: 49

Books

Lars-Åke Levin, Karin Sennfält, Magnus Janzon, Martin Henriksson, Agneta Andersson and Lars Bernfort
  En introduktion i hälsoekonomi
    AstraZeneca Sverige AB, 2004.


Conference Articles

Lars Bernfort, Olle Reichard and Karin Sennfält
  Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
  Health Technology Assessment International,2005, 2005.


Lars Bernfort, Olle Reichard and Karin Sennfält
  Kostnadseffektiviteten av peginterferon alfa-2b (PegIntron) jämfört med interferon alfa-2b (Intron A) vid kombinationsbehandling av kronisk hepatit C i Sverige
  Svenska Läkaresällskapets riksstämma,2004, 2004.


Ph.D. Theses

Karin Sennfält
  Economic studies of health technology changes in prostate cancer care
  2005.


Reports

Peter Bistoletti and Karin Sennfält
  En hälsoekonomisk modellstudie av primärscreening mot livmoderhalscancer med cellprov- och HPV DNA-test
  CMT Rapport, 2008:1, 2008.


  Fulltext PDF